Skip to content

Addiction: all studies

Page 379 of 863: studies 3,781 to 3,790 of 8,627, newest first. Back to the addiction overview

Research

Ketamine for depressive symptoms: A retrospective chart review of a private ketamine clinic.

South African Journal of Psychiatry 2024 Vidette M Juby, Saaeda Paruk, Mitsuaki Tomita et al. 3 citations

There is currently no published evidence demonstrating the effectiveness and safety of subanaesthetic doses of ketamine, when administered intravenously as an adjunct treatment for depressive symptoms, in a real world setting in South Africa. This retrospective chart review reports the clinical response (change in Patient Health Questionnaire - 7 score) to an initial infusion series of ketamine...

DOI: 10.4102/sajpsychiatry.v30i0.2176 (opens in new tab) Full text (opens in new tab) Induction Intravenous Maintenance Major depression +4

Conflict monitoring and emotional processing in 3,4-methylenedioxymethamphetamine (MDMA) and methamphetamine users - A comparative neurophysiological study.

NeuroImage: Clinical 2024 Antje Opitz, Josua Zimmermann, David M. Cole et al. 2 citations

In stimulant use and addiction, conflict control processes are crucial for regulating substance use and sustaining abstinence, which can be particularly challenging in social-affective situations. Users of methamphetamine (METH, "Ice") and 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") both experience impulse control deficits, but display different social-affective and addictive profiles....

Exploring the multifaceted potential of (R)-ketamine beyond antidepressant applications.

Frontiers in Pharmacology 2024 Senbing Zhang, Yanzhu Pu, Jianning Liu et al. 12 citations

(R, S)- and (S)-ketamine have made significant progress in the treatment of treatment-resistant depression (TRD) and have become a research focus in recent years. However, they both have risks of psychomimetic effects, dissociative effects, and abuse liability, which limit their clinical use. Recent preclinical and clinical studies have shown that (R)-ketamine has a more efficient and lasting...

DOI: 10.3389/fphar.2024.1337749 (opens in new tab) Full text (opens in new tab) R-ketamine Antidepressant efficacy Cognitive disorders Ischemic stroke +6

Facts and myths about use of esketamine for treatment-resistant depression: a narrative clinical review.

Frontiers in Psychiatry 2024 Matteo Di Vincenzo, Vassilis Martiadis, Bianca Della Rocca et al. 31 citations

Treatment-resistant depression (TRD) occurs when at least two different antidepressants, taken at the right dosage, for adequate period of time and with continuity, fail to give positive clinical effects. Esketamine, the S-enantiomer of ketamine, was recently approved for TRD treatment from U.S. Food and Drug Administration and European Medicine Agency. Despite proved clinical efficacy, many...

Ketamine modulates disrupted in schizophrenia-1/glycogen synthase kinase-3β interaction.

Frontiers in Molecular Neuroscience 2024 Jia-Ren Liu, Xiao Hui Han, Koichi Yuki et al. 4 citations

Disrupted in schizophrenia-1 (DISC1) is a scaffolding protein whose mutated form has been linked to schizophrenia, bipolar affective disorders, and recurrent major depression. DISC1 regulates multiple signaling pathways involved in neurite outgrowth and cortical development and binds directly to glycogen synthase kinase-3β (GSK-3β). Since ketamine activates GSK-3β, we examined the impact of...

Drug-induced musical hallucination.

Frontiers in Pharmacology 2024 Brock Bakewell, Michael P. Johnson, Madison Lee et al. 4 citations

Musical hallucination is a rare perceptual phenomenon wherein individuals hear music in the absence of external auditory stimuli. This phenomenon occurs across diverse medical conditions and can be triggered by some drugs. The underlying mechanism of drug-induced hallucination is unknown. This study explores drug-induced musical hallucination through a literature review, aiming to investigate...

DOI: 10.3389/fphar.2024.1401237 (opens in new tab) Full text (opens in new tab) Drug side effect Drugs-induced musical hallucination Mechanism Treatment +5

Ketamine Induced Acute Systolic Heart Failure.

European journal of case reports in internal medicine 2024 Fares Saliba, Jonathan Mina, Laurence Aoun et al. 4 citations

Studies have shown major cardiovascular effects associated with ketamine use disorder including dose-dependent negative inotropic effects. Preoperative ketamine use has been linked to ketamine-induced stress cardiomyopathy. A 28-year-old female with a history of recurrent cystitis and ketamine use disorder (twice weekly for 14 years) presented with bilateral lower extremity oedema and shortness...

DOI: 10.12890/2024_004470 (opens in new tab) Full text (opens in new tab) Ketamine-induced disorder Systolic heart failure Ketamine abuse Drug-induced cardiomyopathy +2

Hepatic injury and hepatic failure adverse events in 3,4-methylenedioxymethamphetamine users reported to the FDA Adverse Event Reporting System.

Frontiers in Psychiatry 2024 Tigran Makunts, Ruben Abagyan 2 citations

3,4-Methylenedioxymethamphetamine (MDMA) is being investigated in controlled clinical trials for use as an adjunct medication treatment for post-traumatic stress disorder. MDMA is metabolized by N-demethylation, primarily by CYP2D6, to its main inactive metabolite, 4-hydroxy-3-methoxymethamphetamine. It is also metabolized to a lesser extent by CYP1A2, CYP2B6, and CYP3A4 to its active...

DOI: 10.3389/fpsyt.2024.1414622 (opens in new tab) Full text (opens in new tab) Molly Ddi drug-drug interaction Faers MDMA 3,4-Methylenedioxymethamphetamine +5

The dynamic strategy shifting task: Optimisation of an operant task for assessing cognitive flexibility in rats.

Frontiers in Psychiatry 2024 Jonathan Martin Flintoff, Suzy Alexander, James Paul Kesby et al. 3 citations

Although schizophrenia is associated with a broad range of symptoms including hallucinations, delusions, and reduced motivation, measures of cognitive dysfunction, including cognitive flexibility and executive function, are the strongest predictors of functional outcomes. Antipsychotic medications are useful for reducing psychotic symptoms, but they are ineffective at improving cognitive...

DOI: 10.3389/fpsyt.2024.1303728 (opens in new tab) Full text (opens in new tab) Cognitive flexibility Neuropsychiatric disease Operant tasks Strategy-shifting +5

Sex-specific effects of subchronic NMDA receptor antagonist MK-801 treatment on hippocampal gamma oscillations.

Frontiers in Neuroscience 2024 Tim Simon Neuhäusel, Zoltan Gerevich 5 citations

N-methyl-D-aspartate (NMDA) receptor antagonists are widely used to pharmacologically model schizophrenia and have been recently established in the treatment of treatment-resistant major depression demonstrating that the pharmacology of this substance class is complex. Cortical gamma oscillations, a rhythmic neuronal activity associated with cognitive processes, are increased in schizophrenia...

DOI: 10.3389/fnins.2024.1425323 (opens in new tab) Full text (opens in new tab) Ketamine Cognition Electroencephalography EEG Electrophysiology +6